Sven Wind

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

Sabine Heumüller, Sven Wind, Eduardo Barbosa‐Sicard et al. · Hypertension · 2007 · 730 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

Comparative pharmacology of chemically distinct NADPH oxidase inhibitors

Sven Wind, Knut Beuerlein, Thomas Eucker et al. · British Journal of Pharmacology · 2010 · 236 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Nancy U. Lin, Eric P. Winer, Duncan Wheatley et al. · Breast Cancer Research and Treatment · 2012 · 194 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou et al. · Annals of Oncology · 2016 · 188 citations

Pharmacy, Oncology, Pharmacology +17

Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition

Sven Wind, Knut Beuerlein, M.E. Armitage et al. · Hypertension · 2010 · 178 citations · Full text

Life Sciences, Pharmacology, Physiology +17